GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
I-Mab (IMAB) stock jumped 15% Monday after the biotech company said it plans to focus on developing givastomig for the treatment of gastric cancers. Read more here.
I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...
I-Mab, a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...
Dec. 11, 2024 — Investigators who previously found that a daily statin pill helps prevent heart attacks and strokes in people with HIV have now discovered a potential mechanism that may help to ...
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...
Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a paper published in the ...
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...
Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women’s Hospital, is the corresponding author of a paper published in the Journal of Clinical Oncology, “Comparative Analysis ...